Subscribe To
Agios pharmaceuticals to present broad set of clinical and translational data in rare blood disorders at 65th ash annual meeting and exposition
– Both Mitapivat Dose Arms Achieved statistically Significant Hemoglobin Response in Phase 2 Portion ...
November 2, 2023, 9:05 am
: merck’s keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing che...
October 20, 2023, 12:13 pm
Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...
October 20, 2023, 8:13 am
Us equities bleed again, breaking yesterday's lows
Cue the sad trumpet noises...The early gains in US equities are gone and they're now trading at the lows of the day, even with US yields well off the ...
October 19, 2023, 3:26 pm
Why akero therapeutics stock is crashing today
Akero's experimental NASH drug efruxifermin (EFX) missed its primary endpoint in a phase 2b study. However, st...
October 10, 2023, 11:44 am
Merck immunotherapy shows further promise in lung cancer
Merck & Co confirmed that its cancer drug Keytruda has successfully met the second of its two primary targets in a phase III clinical trial, showi...
October 10, 2023, 9:11 am
Akero's drug for fatty liver disease misses main trial goal
Akero Therapeutics said on Tuesday a mid-stage trial for its drug to treat a type of fatty liver disease showed improvement in patients, but the resul...
October 10, 2023, 7:33 am
Kalvista's sebetralstat: a pill worth swallowing in hae
KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and i...
October 1, 2023, 12:05 am
Novartis (nvs) lutathera meets primary goal in phase iii study
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningf...
September 25, 2023, 1:32 pm
Astrazeneca breast cancer drug gives drugs giant £5bn boost
AstraZeneca PLC (LSE:AZN)'s share price surged by 2.6%, adding nearly £5 billion to the company's market value, following the announcement of encoura...
September 22, 2023, 7:33 am
Astrazeneca signals strong results from breast cancer drug trial
AstraZeneca PLC (LSE:AZN) has hailed strong results from an ongoing trial on the effects of drug datopotamab deruxtecan in breast cancer patients. Acc...
September 22, 2023, 2:54 am
: travere therapeutics shares plunge as kidney-disease treatment has mixed results in trial
Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday after the company released data from a late-stage study of Filspari in IgA nep...
September 21, 2023, 4:46 pm
Fda accepts merck (mrk) snda for welireg in renal cell carcinoma
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved sta...
September 20, 2023, 12:02 pm
Acelyrin (slrn) fails to meet goal in hs study, stock down 54%
ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis ...
September 13, 2023, 11:16 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<...
August 27, 2023, 10:15 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<...
August 27, 2023, 10:15 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<...
August 27, 2023, 10:15 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<...
August 27, 2023, 10:15 am
Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<...
August 27, 2023, 10:15 am
Merck's (mrk) welireg meets renal cell carcinoma study goals
Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant...
August 21, 2023, 3:02 pm